These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19557456)

  • 21. Leucoreduction and variant Creutzfeldt-Jakob disease.
    Darabi K; Dzik WH; Stowell CP; Saito Y
    Transfus Med; 2005 Aug; 15(4):335. PubMed ID: 16101813
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal leucodepletion to reduce potential risk of transmission of new-variant Creutzfeld-Jakob disease.
    Turner M
    Br J Haematol; 2000 Sep; 110(3):745-8. PubMed ID: 10997991
    [No Abstract]   [Full Text] [Related]  

  • 24. Creutzfeldt-Jakob disease and transplantation: facts and fables.
    Dormont D
    Transplant Proc; 1996 Oct; 28(5):2931-3. PubMed ID: 8908129
    [No Abstract]   [Full Text] [Related]  

  • 25. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products.
    Burthem J; Roberts DJ
    Br J Haematol; 2003 Jul; 122(1):3-9. PubMed ID: 12823340
    [No Abstract]   [Full Text] [Related]  

  • 26. Is Creutzfeldt-Jakob disease transmitted in blood? Is the absence of evidence of risk evidence of the absence of risk?
    Ricketts MN
    CMAJ; 1997 Nov; 157(10):1367-70. PubMed ID: 9371066
    [No Abstract]   [Full Text] [Related]  

  • 27. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Nov; 91(4):348. PubMed ID: 17105612
    [No Abstract]   [Full Text] [Related]  

  • 28. Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard?
    Sutton JM; Dickinson J; Walker JT; Raven ND
    Clin Infect Dis; 2006 Sep; 43(6):757-64. PubMed ID: 16912952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies to reduce transfusion acquired vCJD.
    Wallis JP
    Transfus Med; 2011 Feb; 21(1):1-6. PubMed ID: 21070399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 31. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.
    Brown P
    Haemophilia; 2007 Dec; 13 Suppl 5():33-40. PubMed ID: 18078395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA; Turner ML
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.
    Peden AH; Head MW; Ritchie DL; Bell JE; Ironside JW
    Lancet; 2004 Aug 7-13; 364(9433):527-9. PubMed ID: 15302196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Under pressure.
    Siddall R
    Health Serv J; 2003 Aug; 113(5869):12-3. PubMed ID: 12953390
    [No Abstract]   [Full Text] [Related]  

  • 35. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. vCJD and dental treatment: where are we now?
    Whitworth C
    Prim Dent Care; 2007 Jul; 14(3):83-4. PubMed ID: 17650381
    [No Abstract]   [Full Text] [Related]  

  • 37. Panel Discussion. Millennium Festival of Medicine--Transfusion 2020--18 October 2000.
    Fogden M; Whitehorn K; Starr D; Persaud R; Hannaford R; Barbara J; Love E; Robinson A; Ferguson E; Turner G; Wallington T; Klein H; Franklin I; Fry R
    Transfus Med; 2001 Apr; 11(2):136-45. PubMed ID: 11583001
    [No Abstract]   [Full Text] [Related]  

  • 38. New variant Creutzfeldt-Jakob disease: a controversial but potential blood transfusion risk.
    Basu A
    Nepal Med Coll J; 2003 Jun; 5(1):51-2. PubMed ID: 16583978
    [No Abstract]   [Full Text] [Related]  

  • 39. Is Creutzfeldt-Jakob disease transmitted in blood?
    Ricketts MN; Cashman NR; Stratton EE; ElSaadany S
    Emerg Infect Dis; 1997; 3(2):155-63. PubMed ID: 9204296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.